Nemifitide
weak data
The Dose Guy’s verdictOct 27, 20264 sources
Nemifitide is the rare grey-shelf peptide with actual depression trials behind it, and the signal in them is real if uneven: fast onset, a short course of shots, and an effect that outlasted the drug by weeks. The catch is that the program stalled before phase 3, so you’d be injecting a big daily dose of an abandoned antidepressant with no long-term safety data and no clean supply. For most people that is hard to justify when approved antidepressants exist and a prescriber can get you one. If you’re curious, respect what the trials found; if you’re depressed, start with the approved options.
What it is
A short synthetic peptide, five amino acids, built off MIF-1, a tiny brain peptide that showed antidepressant hints decades ago. The developer took it through a string of small depression trials in the late 1990s and 2000s as a fast-acting injectable, the pitch being a few days of shots instead of the slow weeks-long ramp of a daily pill. Then the money ran out before the big confirmatory trial, and it has sat on the shelf since. Nobody ever pinned down exactly how it works; the one human mechanism result points at serotonin handling, but that is a clue, not a map.
That makes it a different animal from the rest of this column. Pregabalin and selank are about taking the edge off anxiety, and propranolol blocks the shaking hands. Nemifitide was aimed squarely at major depression, which puts its real competition outside the peptide world: the approved antidepressants, from an SSRI to agomelatine to an old MAOI like tranylcypromine, and the fast-acting clinic option, esketamine.
What the research shows
Real human trials, all small, all from one developer, and all before 2009. The results were mixed, but they hold together better than most of this shelf:
Realistic protocols
There is no community protocol worth the name here. Almost nobody runs nemifitide, so the only honest map is the shape the trials used, and that shape is unusual: not a daily dose you hold forever, but a short burst of daily sub-q shots, then nothing, then a repeat course only when mood slides back. You don’t titrate it and you don’t chase it. A course either lands or it doesn’t, and in the trials it landed within days if it was going to.
Two practical problems sit on top of that. First, the trial doses are large for a peptide, tens of milligrams a day, which means you are injecting a lot of whatever is actually in a research chemical vial. Demand a third-party COA for identity and purity or don’t bother. Second, nobody studied it alongside other antidepressants. Do not stop a prescription to try this, and do not stack it on an SSRI or an MAOI on your own.
Daily life: skip alcohol for the course and the weeks after. Alcohol is a depressant, it muddies whether the course did anything, and depression plus booze is a bad pairing on any drug. Keep a simple daily mood log from a few days before the first shot, so you can actually tell whether it worked rather than guessing.
Side effects
In the trials it was surprisingly quiet. The unknowns are the problem, not the knowns:
